Cell cycle arrest by oxaliplatin on cancer cells
- 27 March 2007
- journal article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 21 (2) , 165-172
Abstract
Oxaliplatin (L‐OHP) is the only platinum compound to show activity in colorectal cancer. We evaluated the cytotoxicity of L‐OHP on four human cancer cell lines and its influence on the cell cycle, when treated during long exposure (72 h) and different post‐incubation times (24 or 72 h). We used a panel of cell lines: HT29 (colon cancer), MCF7 (breast cancer), Hela (uterine cervix) and A549 (lung adenocarcinoma). Inhibition concentration (IC)50 was assessed by MTT assay. Cell cycle modifications were determined using dual parameter bromodeoxyuridine and propidium iodide. L‐OHP yielded a superior cytotoxicity on HT29 and MCF7 relative to Hela and A549 after treatment, the post‐incubations demonstrate that growth inhibition was irreversible for HT29 and Hela cell lines contrary to MCF7 and A549. The main effects of L‐OHP are G2/M cell cycle arrest and transient S phase delay. Taken together, L‐OHP treatment results on HT29, MCF7 and Hela, are in favor of lengthening the infusion duration to patients during further clinical trials.Keywords
This publication has 18 references indexed in Scilit:
- ATM and related protein kinases: safeguarding genome integrityNature Reviews Cancer, 2003
- High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)European Journal of Cancer, 2001
- OxaliplatinDrugs, 2000
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancerCancer, 1992
- Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.Journal of Clinical Oncology, 1991
- Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Journal of Clinical Investigation, 1991
- Analysis of Events Associated With Cell Cycle Arrest at G2 Phase and Cell Death Induced by CisplatinJNCI: Journal of the National Cancer Institute, 1990
- Flow cytometric analysis of the kinetic effects of cisplatin on lung cancer cellsCytometry, 1989
- In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein crosslinking, and inhibition of replicationBiochemistry, 1985